Tirze-Pep

Tirze-Pep Dragon Pharma

Tirzepatide is a novel, once-weekly injectable dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This pharmacological agent is designed to enhance glucose-dependent insulin secretion and suppress glucagon secretion from the pancreas, thereby regulating postprandial (after-meal) blood glucose levels. Additionally, tirzepatide promotes weight loss by inducing satiety and reducing food intake. It is being developed for the treatment of type 2 diabetes mellitus and other metabolic disorders. The scientific principle behind its action involves activating the GIP and GLP-1 receptors, which are involved in the body's natural response to food intake, ultimately leading to improved glycemic control and potential benefits in cardiovascular health.